The Toronto-Dominion Bank Acquires 5.4% Stake in UroGen Pharma Ltd.

The Toronto-Dominion Bank, along with its subsidiary TD Securities Inc., filed a Schedule 13G on May 15, 2026, disclosing a new 5.4% ownership stake in UroGen Pharma Ltd. (URGN). As of the event date on March 31, 2026, the reporting persons collectively held 2,618,020 ordinary shares. Specifically, The Toronto-Dominion Bank reported sole voting and dispositive power over 2,616,714 shares, while TD Securities Inc. reported sole power over 1,306 shares. The filing indicates that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This represents a significant increase from a previously reported 0% position, marking a new substantial holding by the Canadian financial institution in the biopharmaceutical company. The filing was executed jointly by both entities, with The Toronto-Dominion Bank maintaining an indirect interest in the shares held by its subsidiary.